Vaginal dilator therapy for pelvic cancer patients: a review

Vulvovaginal atrophy affects up to 84% of postmenopausal women and is even more prevalent among cancer survivors. Hypoestrogenism leads to thinning of vaginal epithelium, decreased elasticity, reduced lubrication, and increased tissue fragility, resulting in symptoms such as vaginal dryness, irritation, dyspareunia, and pain with pelvic examination. Cancer treatments-including chemotherapy, endocrine therapy, pelvic radiation, and gynecologic surgery-can induce abrupt estrogen deficiency and accelerate vulvovaginal atrophy beyond what seen in natural menopause. Pelvic radiation in particular is associated with long-term vaginal toxicity, including fibrosis, shortening, and stenosis, which may impair sexual function and limit adequate pelvic examination. Rates of clinically significant vaginal stenosis after chemoradiation for cervical cancer may exceed 30% without preventive intervention. Vaginal dilator therapy is a commonly recommended non-hormonal strategy intended to mechanically stretch vaginal tissues, prevent adhesions, and maintain vaginal patency following cancer treatment. Dilators are cylindrical devices available in multiple sizes and materials, with gradual progression in size recommended to improve vaginal elasticity and tolerance. Lubricants-preferably water-based and physiologically compatible in pH and osmolality-are essential to reduce friction and improve comfort during use. Prospective evidence, although limited, suggests vaginal dilator therapy may reduce the severity of vaginal stenosis. Randomized and observational studies demonstrate decreased stenosis progression, improved dilator tolerance, and better sexual function when therapy is initiated early and used consistently. However, adherence remains a major barrier, with many patients unable to maintain recommended frequency of use. Improved patient education, early access to dilators, and supportive follow-up may enhance adherence and therapeutic benefit.